Table 2. Baseline characteristics for all cirrhosis patients stratified on MAIT%/T-cells in quartiles.
| MAIT cells/T-cells in quartiles | % MAIT cells/T-cells Quartile 1 (n = 27) | % MAIT cells/T-cells Quartile 2 (n = 26) | % MAIT cells/T-cells Quartile 3 (n = 27) | % MAIT cells/T-cells Quartile 4 (n = 26) | P-value |
|---|---|---|---|---|---|
| Age median (IQR) | 70 (59–73) | 63 (52–68) | 61 (54–69) | 58 (52–68) | 0.05 |
| Sex % men | 13 (48%) | 18 (69%) | 19 (70%) | 18 (69%) | 0.27 |
| MELD-Na median (IQR) | 13 (8–17) | 13 (10–16) | 12 (8–18) | 11 (8–14) | 0.66 |
| %MAIT/T-cells median (IQR) | 0.20 (0.13–0.24) | 0.57 (0.41–0.69) | 1.17 (0.89–1.87) | 4.90 (2.99–6.35) | <0.01 |
| Cause for cirrhosis (n, % etiology of each MAIT quartile) | 0.12 | ||||
| NAFLD | 7 (26%) | 4 (15%) | 0 | 3 (12%) | |
| Alcohol | 10 (37%) | 15 (58%) | 13 (48%) | 15 (58%) | |
| Hepatitis C | 2 (8%) | 4 (16%) | 6 (22%) | 4 (15%) | |
| Autoimmune | 5 (19%) | 3 (12%) | 5 (19%) | 4 (15%) | |
| Cryptogenic/other | 3 (11%) | 0 | 3 (11%) | 0 | |
| LAB | |||||
| Bilirubin micromole/L median (IQR) | 21 (12–39) | 22 (13–35) | 23 (11–48) | 12 (9–35) | 0.44 |
| PK-INR (IQR) | 1.2 (1.1–1.4) | 1.2 (1.1–1.4) | 1.2 (1.1–1.5) | 1.2 (1.1–1.3) | 0.96 |
| Albumin (IQR) | 32 (24–34) | 31 (26–38) | 34 (26–37) | 33 (28–36) | 0.37 |
| Platelets (IQR) | 149 (105–195) | 158 (115–204) | 144 (100–195) | 131 (90–179) | 0.74 |
| Leukocytes (IQR) | 6.6 (4.9–8.0) | 5.8 (4.4–7.0) | 5.4 (4.2–7.2) | 6.2 (3.7–7.1) | 0.57 |
| Neutrophils (IQR) | 3.6 (2.1–4.9) | 3.6 (2.3–4.8) | 3.7 (2.3–4.8) | 3.7 (2.3–4.2) | 0.95 |
| Ascites n (% of quartile) | |||||
| No ascites | 15 (55%) | 17 (65%) | 15 (55%) | 12 (46%) | |
| Controlled by diuretics | 4 (15%) | 2 (8%) | 4 (15%) | 5 (19%) | |
| Paracentesis or increased diuretics the past 6 months | 6 (22%) | 6 (23%) | 7 (26%) | 7 (27%) | |
| TIPS | 2 (7%) | 1 (4%) | 1 (4%) | 2 (8%) | |
| Encephalopathy n (% of quartile) | 0.24 | ||||
| No encephalopathy | 23 (85%) | 23 (88%) | 24 (89%) | 26 (100%) | |
| Mild HE grade 1–2 | 4 (15%) | 3 (12%) | 2 (7%) | 0 | |
| Severe HE grade 3–4 | 0 | 0 | 1 (4%) | 0 | |
| Varices n (% of quartile). | 0.40 | ||||
| No varices | 15 (58%) | 18 (69%) | 14 (52%) | 12(46%) | |
| Varices, no bleeding | 9 (35%) | 7 (27) | 13 (48%) | 13 (50%) | |
| Varices, bleeding within 6 months from baseline | 2 (7%) | 1 (4%) | 0 | 1 (4%) | |
| Child-Pugh class n (% of quartile) | 0.84 | ||||
| Child-Pugh A | 12 (44%) | 12 (46%) | 14 (52%) | 14 (54%) | |
| Child-Pugh B | 12 (44%) | 9 (35%) | 7 (26%) | 8 (31%) | |
| Child-Pugh C | 3 (12%) | 5 (19%) | 6 (22%) | 4 (15%) | |
Abbreviations: MAIT cells mucosal-associated invariant T-cells, IQR interquartile range, MELD model of end-stage liver disease, NAFLD non-alcoholic fatty liver disease, TIPS trans jugular intrahepatic portosystemic shunt, BMI body mass index, HE hepatic encephalopathy.